hyaluronoglucosaminidase has been researched along with etoposide in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bernhardt, G; Czech, T; Fuiko, R; Hawliczek, G; Köller, U; Nirnberger, G; Pillwein, K; Slavc, I | 1 |
| Chang, NS | 1 |
2 other study(ies) available for hyaluronoglucosaminidase and etoposide
| Article | Year |
|---|---|
Hyaluronidase additional to standard chemotherapy improves outcome for children with malignant brain tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Child; Etoposide; Female; Humans; Hyaluronoglucosaminidase; Male; Middle Aged; Neoplasm Recurrence, Local; Treatment Outcome | 1998 |
The non-ankyrin C terminus of Ikappa Balpha physically interacts with p53 in vivo and dissociates in response to apoptotic stress, hypoxia, DNA damage, and transforming growth factor-beta 1-mediated growth suppression.
Topics: Animals; Ankyrins; Apoptosis; Cell Division; Cell Line; Cell Nucleus; COS Cells; Cytosol; DNA Damage; DNA-Binding Proteins; Dose-Response Relationship, Drug; Down-Regulation; Etoposide; Genes, Dominant; Humans; Hyaluronoglucosaminidase; Hypoxia; I-kappa B Proteins; Liver; Mice; Microscopy, Fluorescence; Mutagenesis, Site-Directed; NF-KappaB Inhibitor alpha; Phosphorylation; Precipitin Tests; Proline; Protein Binding; Protein Structure, Tertiary; Rats; Recombinant Proteins; Serine; Spleen; Staurosporine; Threonine; Time Factors; Transfection; Transforming Growth Factor beta; Transforming Growth Factor beta1; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Ultraviolet Rays | 2002 |